![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 8, 5710-5717, February 25, 2000
From the Laboratory of Molecular Neuroscience, Institute of Biochemistry, Faculty of Medicine, University of Cologne, D-50931 Cologne, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Sphingomyelinases (SMases) catalyze the
hydrolysis of sphingomyelin, an essential lipid constituent of the
plasma membrane, lysosomal membranes, endoplasmic reticulum, and the
Golgi membrane stacks of mammalian cells. In this study, we report the
biochemical and functional characterization and subcellular
localization of magnesium-dependent nSMase1 from
overexpressing human embryonic kidney (HEK293) cells. Site-directed
mutagenesis of conserved residues probably involved in the enzymatic
sphingomyelin cleavage as well as the removal of one or both putative
transmembrane domains lead to the complete loss of enzymatic activity
of human nSMase1 expressed in HEK293 cells. Polyclonal antibodies
raised against recombinant mammalian nSMase1 immunoprecipitated and
inactivated the enzyme in membrane extracts of overexpressing HEK293
cells and different murine tissues. Cell fractionation combined with immunoprecipitation studies localized the nSMase1 protein predominantly in the microsomal fraction. The enzyme colocalized with marker proteins
of the endoplasmic reticulum and the Golgi apparatus in
immunocytochemistry. Anti-nSMase1 antibodies did not affect the nSMase
activity in the plasma membrane fraction and membrane extracts from
murine brain. Our study leads to the conclusion that nSMase1 is one of
at least two mammalian neutral sphingomyelinases with different
subcellular localization, tissue specificity, and enzymatic properties.
Sphingomyelin is ubiquitously present in eukaryotic cells
distributed in a gradient fashion from membranes of the endoplasmic reticulum, Golgi apparatus, and lysosomes to the plasma membrane which
contains 70-90% of total cellular sphingomyelin. Sphingomyelinases (SMases1; EC 3.1.4.12)
catalyze the hydrolysis of sphingomyelin to ceramide and
phosphocholine. Ceramide is further degraded to sphingosine and fatty
acid by ceramidase(s). Since their discovery 3 decades ago, several
SMase isoforms, including alkaline SMase (1, 2), lysosomal acidic SMase
(aSMase) (3, 4), secreted Zn2+-dependent acidic
SMase (5), membrane-bound Mg2+-dependent SMase
(nSMase) (6-8), and cytosolic Mg2+-independent SMase (9),
have been described. These enzymes differ in their subcellular
localization, tissue specificity, and enzymatic properties, especially
pH optimum (10).
aSMase and nSMases release ceramide in the "sphingomyelin cycle"
(11, 12). Ceramides are regarded as lipid "second messenger" molecules involved in numerous and very divergent cellular functions (10), e.g. in the regulation of cell differentiation (13), apoptosis induced by tumor necrosis factor In order to define the controversially discussed functions of SMases in
cellular processes (19-22), the isolation and molecular characterization of these enzymes is urgently needed.
Recently, we described the cloning of the first mammalian neutral
sphingomyelinase (nSMase1) (23). nSMase1 is a member of an extensive
Mg2+-dependent phosphodiesterase family. The
murine nSMase1 (mnSMase1) cDNA encodes a 419-amino acid residue
protein, and the human enzyme, hnSMase1 (47.6 kDa), contains 423 residues. Both proteins show no obvious signal sequence. The
hydrophobicity plot reveals two transmembrane domains in the C-terminal
part and suggests a bitopic membrane topology with the N and C termini
facing the cytosol.
We describe in this report the expression of tagged nSMase1 in human
embryonic kidney (HEK293) cells, the affinity purification of the
enzymatically active protein to apparent homogeneity, and subsequent
biochemical characterization as well as studies on potential
posttranslational modifications and site-directed mutagenesis of
conserved residues believed to be essential for catalytic activity. The
enzymatic properties of the affinity-purified nSMase1 differ clearly
from a recently published nSMase purified from rat brain (24).
Polyclonal antibodies were raised against complete and truncated murine
and human recombinant nSMase1 protein expressed in Escherichia
coli in order to determine the subcellular distribution and tissue
specificity of nSMase1. The subcellular localization of nSMase1 was
established biochemically, by immunoprecipitation studies and
immunofluorescence microscopy of transfected embryonic fibroblasts.
These approaches underscore that the nSMase1 is predominantly localized
in the membranes of the endoplasmic reticulum.
Anti-nSMase1-specific antibodies inactivated and precipitated the
enzymatic activity from extracts of overexpressing HEK293 cells,
different murine tissues, and microsomal fractions from murine liver
homogenate but did not affect nSMase activity in brain extracts and
plasma membrane fractions. We proved that the residual activity is
contributed by at least one distinct nSMase2, residing in the plasma
membrane and strongly expressed in brain.
Cell Culture and Transfection of HEK293 Cells--
Human
embryonic kidney 293 (HEK293) cells were grown in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum, 100 µg/ml
streptomycin, 100 units/ml penicillin, and 1 mM sodium
pyruvate at 37 °C in a humidified incubator containing 5%
CO2. Stably transfected clones were selected under 1 mg/ml Geneticin (G418; Life Technologies, Inc.). Transiently transfected cells were used 48 h after electroporation.
Measurement of Sphingomyelinase Activity--
nSMase activity
was determined with
N-[14CH3]sphingomyelin as
substrate. Crude membrane extracts from tissues or HEK293 cells were
mixed with 100 mM Tris-HCl, pH 7.4, 5 mM DTT,
0.05% Triton X-100, 5 mM MgCl2, 1× CompleteTM
without EDTA (protease inhibitor set; Roche), and 10 nmol (60,000 dpm)
of N-[14CH3]sphingomyelin in a
total volume of 200 µl. After a 15-30-min incubation at 37 °C,
100 µl of H2O was added, and unreacted substrate was
removed by extraction with 800 µl of
CHCl3/CH3OH (2:1, v/v). 100 µl of the aqueous
phase containing the enzymatically released N-[14CH3]phosphocholine was
counted in a liquid scintillation counter.
Generation of Polyclonal Antibodies--
Truncated (mnSMase1, aa
1-282; hnSMase1, aa 1-271) or complete nSMase1 cDNAs were fused
to a C-terminal c-Myc/His6 tag derived from the plasmid
vector pcDNA3.1/Myc-His (Invitrogen) and expressed in E. coli (BL21(DE3)pLysS) using the pET expression system
(Novagen). Recombinant protein was purified from inclusion bodies using
TalonTM (CLONTECH) according to the manufacturer's
instructions. Rabbit anti-nSMase1 antibodies were raised against these
different recombinant nSMase1 proteins. Recombinant proteins were
coupled to BrCN-activated Sepharose FF (Amersham Pharmacia Biotech) and
used for the affinity purification of nSMase1-directed antibodies.
Aliquots of the purified antibodies were biotinylated using
D-biotinoyl- Combined
Immunoprecipitation/Immunoblotting--
Tissues of
3-month-old CD1 mice or of asmase( Affinity Purification of nSMase1 Protein from Stably Transfected
HEK293 Cells--
HEK293 cells stably transfected with the
mnSMase1/pcDNA3.1/Myc-His construct were sedimented by
centrifugation, resuspended in lysis buffer (50 mM sodium
phosphate, 10 mM Tris-HCl, pH 8.0, 100 mM NaCl,
1× CompleteTM without EDTA) and disrupted by repeated freezing and
thawing. A crude membrane fraction was obtained by centrifugation for 5 min at 2700 × g. Membrane proteins were extracted by
the addition of extraction buffer (lysis buffer plus 0.2% Triton X-100). Insoluble components were removed by ultracentrifugation. nSMase protein was purified by metal-chelating chromatography using
TalonTM (CLONTECH) and immediately adjusted to 5 mM DTT and 20% glycerol.
N-terminal Sequencing of His6-tagged mnSMase1 from
Stably Transfected HEK293 Cells--
mnSMase1 protein was
affinity-purified from HEK293 cells grown on 20 150-mm dishes as
described above and separated by SDS-PAGE. The nSMase1 band was eluted
from the gel and N-terminally sequenced by Edman degradation using a
gas phase sequencer (model 477A; Applied Biosystems).
Subcellular Fractionation of Mouse Liver
Homogenate--
Subcellular fractionation of mouse liver homogenate
was performed according to the method of Fleischer and Kervina (25). The enzymatic activity of glucose-6-phosphatase was measured following the protocol of Swanson (26) using 100 µg of protein, and the activity of 5'-nucleotidase was determined as described using 20 µg
of protein (27).
Site-directed Mutagenesis--
Modified hnSMase1 cDNAs were
obtained by two standard polymerase chain reactions on the basis of the
hnSMase1/pRc/CMV construct, each primed with an "external" and a
modified "internal" oligonucleotide. The internal primers contained
the modified codon and further silent mutations leading to an
additional endonuclease recognition site, which was used to fuse the
polymerase chain reaction products. The external primers allowed the
cloning of the modified cDNAs back into the original expression
vector. The numbers in parentheses indicate the position of the
oligonucleotide in the human nSMase1-cDNA (s, sense; as,
antisense), restriction sites are shown in italics, and bases differing
from the original cDNA are depicted in underlined letters. External
primers were as follows: 5'-CGT CCC CAC CGC GGC CGT CGC TGG-3'
(s289-312) and 5'-CTA TAG AAT AGG GCC CTC TAG ATG CAT G-3' (pRc/CMV
as978-1005). Internal primers were as follows: E49Q, 5'-GCT TTG
CTC GAG CAA GTG TGG AGT G-3' (s483-508); 5'-C ACT CCA CAC TTG CTC GAG CAA AGC-3'
(as483-508); N180H, 5'-GTG GAG ACC TCC
ATA TGC ACC CAG A-3' (s878-901), 5'-T CTG GGT
GCA TAT GGA GGT CTC CAC-3'
(as878-901); H272N: 5'-CCC TCT CTG ATA ATG AAG CGC TGA
TG-3' (s1154-1179), 5'-CA TCA GCG CTT CAT TAT CAG AGA
GGG-3' (as1154-1179). Truncated constructs devoid of one or both
putative transmembrane domains and the C terminus were generated by a
single polymerase chain reaction with the oligonucleotide s289-312
(see above) and one of the following primers: Northern Blot Analysis--
RNA from transfected HEK293 cells
was prepared following the protocol of Chomczynski and Sacchi (28) and
separated on 0.8-1% formaldehyde-agarose gels. After capillary
transfer to GeneScreenPlus membranes (NEN Life Science Products),
hybridization was performed according to the instructions of the
manufacturer. Blots were analyzed with a PhosphorImager 445 SI using
ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA).
Metabolic Labeling of HEK293 Cells and
Immunoprecipitation--
1.5 × 106 transiently
transfected HEK293 cells were grown in methionine-free Eagle's medium
for 1 h and labeled with 150 µCi of
L-[35S]methionine (Amersham Pharmacia
Biotech) for 4 h at 37 °C. Cells were washed with PBS and
resuspended in extraction buffer (0.2% Triton X-100, 10 mM
EDTA, 10 mM EGTA, 50 mM Tris-HCl, pH 7.4, 1×
CompleteTM medium without EDTA). Insoluble material was removed by
ultracentrifugation. nSMase1 protein was precipitated from the extracts
by the addition of affinity-purified anti-hnSMase1 antibody and protein
A-Sepharose (Sigma) and gentle agitation for 1 h at 4 °C in
each case. Sepharose was washed stringently and treated with SDS-PAGE
loading buffer. Proteins were separated by SDS-PAGE (10%). The gel was
dried and analyzed on a PhosphorImager 445 SI (Molecular Dynamics).
Immunofluorescence Microscopy--
107
exponentially growing mouse primary embryonic fibroblasts (EMFIs) were
electroporated with mnSMase1-pRc/CMV, and 48 h later they were
used for immunohistochemistry.
Cells were fixed with 4% paraformaldehyde in PBS and lysed with PBS,
0.5% Triton X-100. After blocking with PBS, 3% bovine serum albumin,
cells were incubated with the anti-mnSMase1 antibody together with
anti-Grp78 (Bip; Biomol), anti-58K (Clone 58K9; Sigma), or
anti-
Human primary fibroblasts were transiently transfected with
hnSMase1-pRc/CMV and hnSMase1-pcDNA3.1/Myc-His (Invitrogen) for 48 h, respectively, and analyzed as described above.
nSMase1 Expression and Affinity Purification of Recombinant nSMase1
and of anti-nSMase1-specific Antibodies--
Complete or truncated
murine and human nSMase1 cDNAs (23) were fused to an N-terminal
Myc-His6-tag and expressed in E. coli. SDS-PAGE
of the bacterial homogenate indicated that the recombinant protein was
present in inclusion bodies. The tagged nSMase1 protein was solubilized
either in 8 M urea or SDS-Triton X-100, adsorbed to a
metal-chelating column (Talon®), and desorbed by
increasing imidazole concentrations from the thoroughly washed column.
All attempts to renature the purified nSMase1 released with 8 M urea from inclusion bodies were unsuccessful. Rabbit
anti-nSMase1 antibodies were raised against the different recombinant
nSMase1 proteins and purified by absorbing to the immobilized antigen.
The antibodies specifically recognize the nSMase1 protein in membrane
extracts from stably transfected HEK293 cells (Fig.
1B).
Biochemical Characterization of Affinity-purified mnSMase from
HEK293 Cells--
HEK293 cells were stably transfected with nSMase1
cDNA cloned into the eukaryotic expression vectors pRc/CMV and
pcDNA 3.1 Myc-His6. Expression of wild type,
mock-transfected cell lines and selected clones was compared on the
mRNA level by Northern and on the protein level by Western blot
analysis and in addition by the enzyme assay (data not shown). HEK293
cells transfected with the tagged and wild type nSMase1 cDNA
expressed the enzyme at a similar rate. Tagged nSMase1 was purified to
apparent homogeneity by metal-chelating affinity chromatography from
overexpressing HEK293 cells (Fig. 1A). The flow-through of
the affinity column showed no significantly increased nSMase activity
compared with membrane extracts from mock-transfected HEK293 cells,
demonstrating that the tagged protein is directly responsible for the
increased nSMase activity in transfected cells. The enzymatic
properties of nSMase1 were unimpaired by the C-terminally fused
c-Myc-His6-tag. We could not detect any other copurified
protein compounds. The specific activity of the affinity purified
enzyme was enriched 50 times compared with its activity in the crude
membrane extract (50 versus 1 µmol of sphingomyelin/h/mg
of protein), but the total nSMase activity was reduced dramatically.
The loss of activity is caused very likely by the absence of reducing
DTT or mercaptoethanol essential in enzyme purification but fatal for
the matrix of the affinity column. Increasing purity also reduced the
enzyme stability. Reducing agents added after affinity purification
were unable to restore the nSMase1 activity. However, the
affinity-purified nSMase1 was used for detailed examination of its
enzymatic properties.
Purified nSMase1 showed a neutral pH optimum and no detectable activity
against phosphatidylcholine. The enzyme was inactive without magnesium
and manganese ions in the assay mixture. Both divalent cations
activated the enzyme but showed different kinetics. Mg2+
(Ka = 80 µM) was effective even at
high concentrations up to 10 mM, while Mn2+
(Ka = 15 µM) inhibited the enzyme at
concentrations above 0.5 mM as described before by
Hostetler and Yazaki (29) for neutral sphingomyelinase from rat liver
homogenate (Fig. 2A). It
reveals a direct activation by arachidonic acid (Ka = 20 µM) (Fig. 2B) but no detectable
stimulation by the phospholipid phosphatidylserine (10-200
µM) or inhibition at physiological glutathione
concentrations as described recently for a brain-specific nSMase
(24).
Putative Posttranslational Modifications--
Recombinant hnSMase1
and mnSMase1 purified either from E. coli or from membrane
extracts of HEK293 cells constantly deviated by 6-7 kDa in molecular
mass in SDS-PAGE from the calculated sizes of 47.5 and 47.6 kDa for
mnSMase1 and hnSMase1 and 50.8 kDa for the tagged murine protein,
respectively (Fig. 3). The band at 42 kDa
represents mnSMase1, and the faint 80-kDa band represents the dimer
(Fig. 3, A (lane 2) and B
(lane 1)). The latter was transformed to the
monomeric 42-kDa band by treatment with the reducing agent DTT (Fig.
3B, lane 2) and by reductive
carboxymethylation (Fig. 3B, lane 3).
Dimerization through disulfide bonds is obviously an artifact of the
purification. This interpretation is supported by the rapid loss of
enzyme activity in the absence of reducing SH reagents.
mnSMase1 and hnSMase1 contain one and two putative consensus sequences
for N-glycosylation. Endoglycosidase H and
N-glycosidase F treatment did not alter the electrophoretic
mobility of the 42-kDa protein band in SDS-PAGE (Fig. 3C).
Therefore, no evidence for glycosylation of native and mature nSMase1
can be found on the basis of our experiments.
mnSMase1 contains 17 cysteines, eight of which are conserved in
hnSMase1. 16 cysteines are located in the putative cytosolic part of
the protein and therefore in the reducing environment, which makes
disulfide bonds highly unlikely.
Other possible causes for the reduced apparent molecular mass were
excluded; Edman degradation of the affinity-purified nSMase1 from
HEK293 cells revealed that the translation starts at the first possible
methionine in the proposed nSMase1 peptide sequence and that no
N-terminal proteolytic truncation had occurred. The successful affinity
purification of the C-terminally tagged enzyme protein excludes also a
C-terminal proteolysis, which could account for the derived molecular
mass of 42 kDa of nSMase1 in SDS-PAGE.
The discrepancy between the calculated and electrophoretic mobility
derived molecular mass may be due to a frequently observed unusual SDS
binding of the hydrophobic protein domains.
Functional Analysis of nSMase1 by Site-directed Mutagenesis of
Potential Catalytic Amino Acid Residues and by Truncation of
nSMase1--
nSMase1 belongs to a large family of phosphodiesterases
including mammalian DNaseI, phospholipase C from S. aureus,
and bacterial sphingomyelinases. They reveal species-independent
identical motifs. This suggests their essential function in the
catalysis of the hydrolysis of the phosphodiester bonds. Relevant to
this study is the prediction of analogous amino acid residues in the
hnSMase1 derived from x-ray crystallography of DNaseI (30). They are either involved in Mg2+ complexing (Glu49) or
substrate binding (Asp111, Tyr141, and
Asn180) or are essential for acid (His151) and
base (His272) catalysis and the stabilization of the
pentavalent transition state of the phosphorus (Asp251).
The hnSMase1 constructs for the analysis of the putative functions of
the respective amino acid residue side chains are given in Fig.
4.
We also studied the function of the two putative transmembrane (TM)
domains. hnSMase1 constructs devoid of the C-terminal part of the
protein and one or both TM domains were established as well as a
construct with the TM helices replaced by the hexapeptide GPTNPG. The
two prolines within the peptide should allow the back-folding of the
C-terminal domain into the predicted conformation of the mature nSMase1.
Point-mutated and truncated constructs of hnSMase1 were transiently
expressed in HEK293 cells. nSMase1 mRNA was quantitated by Northern
blot hybridization analysis (Fig. 5,
A and B). Proteins, immunoprecipitated from
membrane extracts of [35S]methionine metabolically
labeled HEK293 cells were separated by SDS-PAGE and quantitated by
autoradiographic analysis (Fig. 5C). Specific nSMase
activity was measured in the membrane extracts and the 2700 × g supernatant (Fig. 5, D.1 and D.2).
Wild type and the point mutations E49Q, N180H, and H272N showed an
almost identical expression on the mRNA and protein level, but only
cells transfected with wild type hnSMase1 revealed an increase of
nSMase activity. The Northern blot signals of the truncated nSMase1
transcripts were reduced and the protein signals hardly visible in
autoradiography. No increase of nSMase activity was measured in cells
transfected with this cDNA expression constructs. Furthermore, the
truncated nSMase1 proteins were not detectable in immunofluorescence
(data not shown).
Tissue-specific Expression of nSMase1 in the Mouse--
In a first
approach, Western blot analysis with affinity-purified anti-nSMase
antibodies produces only weak signals due to the very low nSMase1
protein concentration in the different murine tissues examined.
Therefore, an immunoprecipitation step was performed prior to the
Western blot analysis; nSMase1 protein was enriched from the
solubilized 2700 × g sediment derived from tissue
homogenates by immunoprecipitation with mnSMase1-specific
affinity-purified antibodies and subsequent adsorbtion to protein
G-Sepharose. The immunocomplex was disrupted by heating in SDS-PAGE
sample buffer and subjected to SDS-PAGE and immunoblotting using
biotinylated anti-mnSMase antibodies. The signal intensities in Western
blot analysis (Fig. 6) corresponded well
to those in Northern blot analysis described previously (23). nSMase
protein is ubiquitously distributed in all tissues examined with the
strongest signal in kidney and of similar size compared with mnSMase1
from transfected HEK293 cells. The absence of a signal in jejunum is
probably due to the high proteolytic activity in this tissue. A
comparison of the expression in these tissues on the transcriptional
(Northern blot signals) and translational level (Western blot signals)
with their nSMase activity, however, revealed a striking difference, particularly in the brain homogenate.
Immunoprecipitation of nSMase1 Activity in Mouse Tissues,
Particularly in Brain, Suggests an Additional
nSMase2--
Immunoprecipitation studies performed with membrane
extracts from stably mnSMase-transfected HEK293 cells revealed a
specific and quantitative precipitation of nSMase1 activity and protein using purified anti-mnSMase1 antibodies and protein G-Sepharose, subsequently (Fig. 7). An
immunoprecipitation study in different murine tissues combined with
nSMase activity measurement in the supernatant after the precipitation
should answer the question of whether nSMase1 is responsible for the
high enzymatic activity in brain despite its low protein amount
compared with the other tissues.
mnSMase1-specific antibodies quantitatively precipitate the nSMase1
protein from crude membrane extracts from mouse brain and kidney
homogenate (Fig. 8A). 75% of
total nSMase activity is inactivated in kidney, therefore corresponding
to nSMase1 inhibition (Fig. 8B), but only a minute part of
the activity in brain homogenate is inactivated by increasing
concentrations of the nSMase1-specific antibody. This suggests a
specific sphingomyelinase nSMase2 responsible for the high nSMase
activity in brain different from the cloned nSMase1 described here.
NSMase1 Is Located in the Endoplasmic Reticulum--
Confocal
immunofluorescence microscopy of EMFIs transiently transfected with
mnSMase-pRc/CMV indicates that nSMase1 resides predominantly in the ER.
Double staining with anti-mnSMase1 antibodies together with anti-Bip
(Grp78; residing in the lumen of the ER) antibodies or anti-58K protein
(microtubule-binding peripheral Golgi membrane protein) antibodies,
respectively, show a colocalization most with the ER, but also
partially with the Golgi complex. Staining with the cytosceletal marker
Fluorescence of the wild type, c-Myc/His-tagged hnSMase1 fusion protein
and the hnSMase1 mutants E49Q, N180H, and H272N colocalized with the
Bip fluorescence (not shown). This also suggests that nSMase1 resides
in the ER but not in the plasma membrane. Pretreatment of the
transfected cells with brefeldin A had no influence on the distribution
of Bip but had induced the retrograde transport of the 58K protein from
the Golgi to the ER (data not shown). The subcellular distribution of
nSMase1 remained almost unimpaired by the brefeldin A treatment, which
again strongly suggests its predominant localization in ER membranes.
The localization of a minor part of the nSMase protein in the Golgi
cannot be excluded.
Combined immunoprecipitation and Western blot analysis of protein
extracts of subcellular compartments of liver confirmed the assignment
of the localization of nSMase1 to the endoplasmic reticulum (Fig.
10B). Cross-contaminations
of subcellular fractions were estimated by the activities of
compartment-specific marker enzymes. 5'-Nucleotidase activity (Fig.
10C) was highest in the plasma membrane fraction but still
detectable in the Golgi fraction also associated with contaminating
microsomes, as monitored by glucose-6-phosphatase activity measurement
(Fig. 10D).
These results indicate the predominant localization of nSMase1 in the
smooth microsomal fraction. The presence in the plasma membrane
fraction must be attributed to cross-contaminating ER membranes.
Immunoprecipitation studies with extracts of subcellular fractions of
mouse liver homogenate point to the existence of at least two
distinguishable nSMase activities located within different subcellular
compartments (Fig. 10, E and F); 75-80% of
neutral sphingomyelinase activity residing in the microsomal fraction was inactivated by the mnSMase1-specific antibodies, but only 35% of
the nSMase activity measured in the plasma membrane fraction is
nSMase1-specific, which is contributed by cross-contaminating nSMase1
residing in the ER fraction. This indicates that the anti-nSMase1 antibody is unable to recognize an additional plasma membrane-specific sphingomyelinase (nSMase2). Nonimmunoprecipitable nSMase activity in
the Golgi fraction may be contributed by plasma membrane-specific nSMase2 on its translocation pathway from the ER to the plasma membrane
or may originate from an additional Golgi-specific nSMase.
In this study, we report the expression, affinity purification,
and detailed characterization of the mouse and human nSMase1 enzyme
protein expressed in HEK293 cells. Essential for these studies was the
availability of nSMase1-specific polyclonal antibodies.
The mammalian nSMase1 is a member of a large family of
Mg2+-dependent phosphodiesterases including
mammalian DNaseI and E. coli exonuclease. The replacement of
any of three highly conserved amino acids against structurally related
residues within the hnSMase peptide sequence completely abolished the
enzymatic activity and provided evidence for the essential function of
residues Glu49, Asn180, and His272
in the catalytic cleavage of sphingomyelin. These results suggest the
analogy of the active center of eukaryotic nSMase1 to that of bacterial
sphingomyelinases, although our experiments cannot rule out the
possibility that conformational changes caused by the mutations are
responsible for the loss of nSMase activity.
The characterization of the affinity-purified nSMase1 from transfected
HEK293 cells led to two important conclusions. First, it was shown that
the predicted nSMase protein is directly responsible for the increased
nSMase activity in HEK293 cells transfected with the corresponding
cDNA. Second, the cloned nSMase1 differs significantly from a
recently published nSMase activity from rat brain (no stimulatory
effect of phosphatidylserine on enzymatic activity) (24) and,
concerning the missing influence of physiological glutathione
concentrations (31, 32), from the nSMase activity that has been
suggested to be involved in intracellular signal transduction pathways.
Additionally, the affinity-purified enzyme showed only a negligible
phospholipase C activity as described previously (33).
Pivotal for understanding the function of this nSMase1 is its tissue
distribution and subcellular localization. Northern as well as Western
blot analyses revealed the ubiquitous distribution of nSMase1 mRNA
and protein in all organs with the strongest expression in kidney and
weakest in spleen and muscle (23). However, nSMase enzyme activity in
brain and jejunum was 500 and 100 times higher than in other tissues.
These measurements are inconsistent with the ubiquitous distribution of
nSMase1 mRNA and protein in all tissues examined and raise the
possibility of the existence of additional nSMase isoenzymes.
NSMase1, overexpressed in HEK293 cells, is completely inactivated by
immunoprecipitation. In mouse kidney extracts, 75% of the total nSMase
activity was inactivated by the antibody, while in membrane extracts of
total mouse brain the nSMase activity was not affected by the
anti-nSMase1 antibody. These results and the results from the
biochemical characterization of nSMase1 indicate the existence of at
least one other nSMase responsible for the high enzymatic activity in brain.
The subcellular localization of nSMase1 in ER membranes was verified by
immunofluorescence studies and analysis of subcellular fractions from
mouse liver homogenate. These results suggest the existence of at least
two different nSMases located in the plasma membrane and the microsomal
fraction. Hostetler and Yazaki (29) described a microsomal nSMase
activity in rat liver homogenate slightly different from the enzyme in
the plasma membrane fraction. The cloned nSMase1 and this enzyme are
probably identical.
The ER localization of nSMase1 raises the question of its function in
several cellular processes. Ceramides play a role in vesicle-membrane
fusion and endocytosis. Sphingomyelinases induce aggregation and fusion
by ceramide release (34). They disturb the bilayer structure in favor
of a nonlamellar, micellar phase (35). Membranes of the ER and Golgi
complex, especially those of smooth ER, constantly participate in
protein and lipid mass transport by local vesicle formation and fusion.
It is conceivable that SNARE-mediated vesicle-membrane fusion (36) is
facilitated by local activation of membrane-bound nSMases. Kidney cells
and jejunum are characterized by their high endocytotic activity. NSMase1 expression is particularly high in these two tissues, supporting this presumption. The high activity of nSMase in gray matter
of brain (37) would enable the budding and fusion of neurotransmitter
vesicles. A regulatory role of nSMase1 within the maintenance of a
constant sphingomyelin content of cellular membranes also cannot be excluded.
Among the proposed functions of nSMases is the release of ceramide in
the "sphingomyelin cycle" and its role in signal transduction. Distinct pools of sphingomyelin within a cell coupled to different subcellular sites of ceramide generation seem to be critical concerning their effects on cell fate (38). The proposed transmembrane domains and
the residual C-terminal part of mammalian nSMases are absent in the
secreted bacterial sphingomyelinases. In order to create a soluble
mammalian nSMase for studies of the proposed importance of the
subcellular site of nSMase action, truncated nSMase1 expression
constructs were generated that lack these domains. The production of
nSMase protein lacking the TM domains was decreased, probably due to
enhanced degradation or reduced stability. Additionally, these proteins
were enzymatically inactive, which made these experiments unnecessary.
However, overexpression of the H272N mutant in stably transfected
Jurkat cells as a dominant negative system did not affect the kinetics
of PARP cleavage (data not shown) as described previously for nSMase1
overexpression (23).
Among the surprising observations were the growth and morphology of
nSMase1-overexpressing HEK293 cells (160-fold), which were
indistinguishable from wild type and mock-transfected cells. Their
sphingomyelin and ceramide content was unchanged. Also, the lipid
analysis of the microsomal fraction of the overexpressing cells
isolated by gradient centrifugation revealed no reduction of the
sphingomyelin concentration (data not shown). This suggests a strongly
regulated nSMase1 activity in the ER membranes only constitutively
activated upon detergent extraction. No response to the enhanced
sphingomyelinase activity either of a ceramidase that may catalyze the
removal of the product of the reaction or of a sphingomyelin synthase
that could balance a potential sphingomyelin degradation by nSMase1 was measured.
A comprehensive insight into the structural and cellular functions of
nSMase1 will be obtained from a nSMase1-deficient mouse model and the
cloning and functional analysis of additional members of the neutral
sphingomyelinase family.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(12, 14) and Fas (15),
and stress-induced apoptosis (16-18). Therefore, increasing attention
has been focused on neutral magnesium-dependent
sphingomyelinases and their participation in a variety of cellular
processes in the recent past; however, their molecular characterization
has resisted all attempts.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-aminocaproic acid-N-hydroxysuccinimide (Roche Molecular Biochemicals)
following the manufacturer's instructions.
/
)
mice were homogenized in homogenization buffer (0.25 M
sucrose, 10 mM EDTA, 10 mM EGTA, 50 mM Tris-HCl, pH 7.4, 2× CompleteTM without EDTA) and
centrifuged for 10 min at 900 × g. 5 mM
DTT was included in the homogenization buffer only in samples used for
measurement of sphingomyelinase activity. The sediment was extracted in
homogenization buffer, 1% Triton X-100 and centrifuged for 60 min at
100,000 × g. Protein concentration in the supernatant
was determined by the BCA protein assay (Pierce) with bovine serum
albumin as a standard. Aliquots of the extracts (2 mg of protein each)
were mixed with 50 µl of immobilized streptavidin (Roche) and
incubated at 4 °C overnight with gentle agitation. After removal of
the streptavidin beads, 10 µl of rabbit anti-nSMase1 serum or
preimmune serum was added to the extracts. After incubation for 1 h at 4 °C, the antigen-antibody complexes were precipitated by the
addition of 50 µl of protein G coupled to cross-linked (4%) agarose
beads (Sigma). After different washing steps, antigen-antibody
complexes were dissociated by heating in SDS-PAGE loading buffer and
separated by 10% SDS-PAGE. Western blot analysis was performed with
biotinylated purified anti-mnSMase1 antibody (1 µg/ml) followed by
stringent washing and incubation with a streptavidin-horseradish
peroxidase conjugate (Sigma). After several washing steps, bands were
visualized by chemiluminescence staining using SuperSignalSubstrate (Pierce).
TM,
C terminus
(5'-CTC TAG ATT AGC GAG CCT GAG CCA TGC CCA
GAC-3'; 1292-1314);
2.TM,
C terminus (5'-CTC TAG
ATT ATT CCC CGG CCC CTC CTC CAG CCG-3'; 1385-1407). A
construct devoid of the transmembrane domains but including the
C-terminal part of hnSMase1 was cloned by the method described above.
The internal primers were used to insert a spacer of six amino acids
(GPTNPG), which replaces the transmembrane domains between the N- and
the C-terminal part of the protein:
TM, +C terminus
(5'-GGG CCC ACC AAC CCC GGG CAC GTA CAG GAG GTC
AAT GGC-3' (s1474-1494) and 5'-CCC GGG GTT GGT GGG
CCC GCG AGC CTG AGC CAT GCC CAG-3' (as1294-1314)).
-tubulin (clone B-5-1-2; Sigma) in PBS, 3% bovine serum
albumin, 0.5% Triton X-100. Cells were washed with PBS, 0.5% Triton
X-100 and PBS three times each and incubated with a Cy3-conjugated
anti-rabbit IgG antibody (Jackson ImmunoResearch) and a Cy2-conjugated
anti-mouse IgG antibody (Jackson ImmunoResearch), washed and analyzed
with a Leica confocal microscope.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (98K):
[in a new window]
Fig. 1.
Affinity purification of
His6-tagged murine nSMase1 protein from stably transfected
HEK293 cells. A, silver-stained SDS-polyacrylamide gel
(10%) of protein fractions from metal-chelating chromatography. Crude
membrane extracts were applied to a 1-ml TalonTM
(CLONTECH) column, and bound protein was eluted
with a stepwise gradient of increasing imidazole concentration. nSMase1
protein eluted from the column at imidazole concentrations above 15 mM. B, Western blot analysis of protein extracts
before (membrane extract) and after purification (50 mM
imidazol). Aliquots of the fractions were separated by (10%) SDS-PAGE,
blotted onto nitrocellulose, and treated with affinity-purified
anti-mnSMase1 antibodies. Second antibody was anti-rabbit
IgG-horseradish peroxidase conjugate. Bands were visualized by
chemiluminescence with SuperSignalSubstrate (Pierce).

View larger version (14K):
[in a new window]
Fig. 2.
Influence of divalent cations and arachidonic
acid on purified murine nSMase1 from stably transfected HEK293
cells. mnSMase1-Myc-His6 fusion protein was purified
by metal-chelating chromatography from crude membrane extracts from
stably transfected HEK293 cells (see Fig. 1). Effectors of nSMase1
activity were added directly to the assay mixture. A,
effects of divalent cations.
, MnCl2;
,
MgCl2. B, activation by arachidonic acid. The
results are mean values of three independent measurements ± S.D.
Ka values were calculated from Lineweaver-Burk plots
of the data indicated in the figure.

View larger version (63K):
[in a new window]
Fig. 3.
Putative post-translational modifications of
nSMase1 protein expressed in HEK293 cells. A,
comparative SDS-PAGE of affinity-purified mnSMase from HEK293 cells
(lane 1) and E. coli (lane
2). Protein bands were visualized by silver staining.
B, Western blot analysis of mnSMase from stably transfected
HEK293 cells after treatment with reducing (DTT) and
carboxymethylating (iodacetamide (IAA)) agents.
C, same as B after treatment with endoglycosidase
H/N-glycosidase F. The arrows indicate
nSMase-specific bands.

View larger version (15K):
[in a new window]
Fig. 4.
Schematic view of mutant hnSMase1
proteins. A-C, mutations of amino acids probably
involved in enzymatic sphingomyelin cleavage. D, hnSMase1
protein without putative TM domains and subsequent C-terminal part.
E, construct without second TM domain and C-terminal part.
F, hnSMase1 with TM domains replaced by the linker peptide
GPTNPG.

View larger version (82K):
[in a new window]
Fig. 5.
Complete loss of nSMase1 activity caused by
different point mutations and removal of the transmembrane
helices. Three point mutations were introduced into the human
nSMase1-cDNA (lanes 3-5) and constructs of
the nSMase1 cDNA generated, which encode the enzyme protein lacking
the transmembrane domains and/or truncated at the C terminus
(lanes 6-8). HEK293 cells were transiently
transfected with these modified cDNAs and analyzed by Northern
blotting, immunoprecipitation, and nSMase activity measurement. Cells
transfected with the expression vector (mock-transfected) and the
unmodified hnSMase1-cDNA served as a control (lanes
1 and 2). A, Northern blot analysis of
total HEK293 cell RNA with hnSMase1-cDNA as a probe. B,
same blot as used in A, rehybridized with a 548-bp
HindIII/XbaI fragment derived from human GAPDH
cDNA. C, immunoprecipitation of the nSMase1 protein from
metabolically [35S]methionine-labeled cells. Cells were
extracted with a Triton X-100 containing buffer and treated
subsequently with affinity-purified anti-hnSMase1 antibodies and
protein A-Sepharose. The immunoprecipitate was separated by SDS-PAGE
and analyzed autoradiographically. D.1, specific nSMase
activity (nmol of sphingomyelin/mg of protein/h) in the 2700 × g sediment of cell homogenates. D.2, specific
nSMase activity (nmol of sphingomyelin/mg of protein/h) in the
2700 × g supernatant of cell homogenates. The crude
fractionation of the cellular homogenat was performed to detect the
expected shift of the nSMase1 protein without transmembrane domains
from a membrane-bound to a soluble condition. In
TM
C terminus, the
complete C-terminal part of the hnSMase1 protein beginning at the first
TM domain (Trp322) was deleted; in
TM2
C terminus, the
C-terminal part starting with the second TM domain (Val353)
was removed; and in
TM +C terminus, the two transmembrane-spanning
domains of hnSMase1 protein (Trp322-Phe374)
were replaced by the oligopeptide GPTNPG.

View larger version (25K):
[in a new window]
Fig. 6.
nSMase1 protein is ubiquitously expressed in
all tissues examined. Protein (2 mg) from membrane extracts of
different murine tissues was subjected to immunoprecipitation with
anti-mnSMase1 serum/protein G-Sepharose. The immunoprecipitate was
separated by SDS-PAGE and analyzed by Western blotting using
affinity-purified biotinylated anti-mnSMase1-antibodies combined with a
streptavidin-horseradish peroxidase conjugate. The blot was developed
by using a chemiluminescent peroxidase substrate.

View larger version (46K):
[in a new window]
Fig. 7.
Anti-mnSMase1 antibodies immunoprecipitate
nSMase1 protein and activity from stably transfected HEK293 cells.
Membrane extracts of HEK293 cells stably expressing the mnSMase1
cDNA were incubated with increasing amounts of anti-mnSMase1 serum
or preimmune serum (PIS) followed by a constant amount of
protein G-Sepharose. The protein G-Sepharose/antigen-antibody complex
was sedimented by centrifugation. A, Western blot analysis
of the supernatant after immunoprecipitation. Biotinylated
anti-mnSMase1 antibodies and the streptavidin-horseradish peroxidase
conjugate was used for immunodetection of nSMase1 protein. Bands were
visualized by chemiluminescence with SuperSignalSubstrate (Pierce).
B, the protein G-Sepharose/antigen-antibody complex was
disrupted by heating in SDS loading buffer and subjected to SDS-PAGE
and Western blot analysis. Fractions of membrane extracts without added
antibody (PBS) (last two lanes) were
used as controls. C, nSMase activity in the supernatant
after immunoprecipitation. nSMase activity was measured in aliquots of
the supernatant of the sedimented protein G-Sepharose/antigen-antibody
complex.

View larger version (42K):
[in a new window]
Fig. 8.
Anti-mnSMase1 antibodies immunoprecipitate
most of the nSMase activity from murine kidney extracts but not from
brain extracts. A, crude membrane extracts from murine
kidney and brain were treated with increasing amounts of anti-mnSMase1
antibody and preimmune serum (PIS). The antigen-antibody
complex was precipitated by the addition of protein G-Sepharose and
analyzed by Western blotting. B, nSMase activity in the
supernatant after immunoprecipitation. nSMase activity was measured in
aliquots of the supernatant after sedimentation of the protein
G-Sepharose/antigen-antibody complex. The results are mean values of
three independent measurements ± S.D.
-tubulin shows a different distribution of the proteins (Fig.
9). Neither mock-transfected or
untransfected EMFIs nor secondary antibodies alone show nSMase staining
(not shown).

View larger version (28K):
[in a new window]
Fig. 9.
nSMase1 immunofluorescence mainly stains the
endoplasmic reticulum. Transiently transfected EMFIs were stained
with anti-mnSMase1 antibody together with anti-58K, anti-Bip, or anti
-tubulin antibodies, respectively, and corresponding Cy2- and
Cy3-conjugated second antibodies and analyzed by confocal microscopy.
A, anti-58K-Cy2; D, anti-Bip-Cy2; G,
anti-
-tubulin-Cy2. B, E, and H,
anti-mnSMase-Cy3. C, F, and I,
superimposition of the Cy2 and Cy3 channels. Yellow color
indicates a colocalization.

View larger version (48K):
[in a new window]
Fig. 10.
nSMase1 protein is predominantly located in
the smooth endoplasmic reticulum. Subcellular fractions were
prepared from mouse liver homogenate by discontinuous sucrose gradient
centrifugation. The purity of the subcellular fractions was tested by
measurement of marker enzymes for endoplasmic reticulum and plasma
membrane. Extracts of the membrane fractions were subjected to combined
immunoprecipitation/Western blot analysis and nSMase activity assay
after immunoprecipitation. Western blot analysis of subcellular
fractions after immunoprecipitation with preimmune serum (A)
and anti-mnSMase1 antibodies (B) is shown. C,
specific activity (µmol of Pi/mg of protein/h) of plasma
membrane marker 5'-nucleotidase. D, specific enzymatic
activity (µmol of Pi/mg of protein/h) of the ER marker
glucose-6-phosphatase. Shown is specific nSMase activity (nmol of
sphingomyelin/mg of protein/h) in membrane extracts after treatment
with preimmune serum (E) and in membrane extracts
precipitable with anti-mnSMase1 serum (F).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
FOOTNOTES |
|---|
* This work was supported by Deutsche Forschungsgemeinschaft Grant SFB 243 and Interdisciplinary Center for Clinical Research Cologne (ZMMK) Project 23.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by a Fogarty Scholarship. To whom correspondence should
be addressed: Laboratorium für Molekulare Neurowissenschaften, Institut für Biochemie, Medizinische Fakultät,
Joseph-Stelzmann-Strasse 52, 50931 Köln, Germany. Tel.:
49-221-478-6881; Fax: 49-221-478-6882; E-mail:
wilhelm.stoffel@uni-koeln.de.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SMase, sphingomyelinase; nSMase, neutral sphingomyelinase; nSMase1 and nSMase2, first and second neutral sphingomyelinase, respectively; aSMase, acidic sphingomyelinase; mnSMase and mnSMase1, murine nSMase and nSMase1, respectively; hnSMase1, human nSMase1; aa, amino acid; PBS, phosphate-buffered saline; HEK293, human embryonic kidney cells 293; DTT, dithiothreitol; ER, endoplasmic reticulum; Bip, immunoglobulin heavy chain binding protein; TM, transmembrane helix; EMFI, exponentially growing mouse primary embryonic fibroblast; PAGE, polyacrylamide gel electrophoresis.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Duan, R. D., Nyberg, L., and Nilsson, A. (1995) Biochim. Biophys. Acta 1259, 49-55[Medline] [Order article via Infotrieve] |
| 2. | Nyberg, L., Dulan, R. D., Axelson, J., and Nilsson, A. (1996) Biochim. Biophys. Acta 1300, 42-48[Medline] [Order article via Infotrieve] |
| 3. |
Kanfer, J. N.,
Young, O. M.,
Shapiro, D.,
and Brady, R. O.
(1966)
J. Biol. Chem.
241,
1081-1084 |
| 4. | Heller, M., and Shapiro, B. (1966) Biochem. J. 9, 763-769 |
| 5. |
Spence, M. W.,
Byers, D. M.,
Palmer, F. B.,
and Cook, H. W.
(1989)
J. Biol. Chem.
264,
5358-5363 |
| 6. | Nilsson, A. (1969) Biochim. Biophys. Acta 176, 339-347[Medline] [Order article via Infotrieve] |
| 7. | Gatt, S. (1976) Biochem. Biophys. Res. Commun. 68, 235-241[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Rao, B. G., and Spence, M. W. (1976) J. Lipid Res. 17, 506-515[Abstract] |
| 9. |
Okazaki, T.,
Bielawska, A.,
Domae, N.,
Bell, R. M.,
and Hannun, Y. A.
(1994)
J. Biol. Chem.
269,
4070-4077 |
| 10. | Liu, B., Obeid, L. M., and Hannun, Y. A. (1997) Semin. Cell Dev. Biol. 8, 311-322[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Linardic, C. M.,
and Hannun, Y. A.
(1994)
J. Biol. Chem.
269,
23530-23537 |
| 12. | Kolesnick, R. N., and Krönke, M. (1998) Annu. Rev. Physiol. 60, 643-665[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Okazaki, T.,
Bell, R. M.,
and Hannun, Y. A.
(1989)
J. Biol. Chem.
264,
19076-19080 |
| 14. |
Adam, D.,
Wiegmann, K.,
Adam-Klages, S.,
Ruff, A.,
and Krönke, M.
(1996)
J. Biol. Chem.
271,
14617-14622 |
| 15. |
Boesen-de Cock, J. G. R.,
Tepper, A. D.,
de Vries, E.,
van Blitterswijk, W. J.,
and Borst, J.
(1998)
J. Biol. Chem.
273,
7560-7565 |
| 16. | Mathias, S., Peña, L. A., and Kolesnick, R. N. (1998) Biochem. J. 335, 465-480 |
| 17. |
Hannun, Y. A.
(1996)
Science
274,
1855-1859 |
| 18. |
Haimovitz-Friedman, A.,
Kan, C. C.,
Ehleiter, D.,
Persaud, R. S.,
McLoughlin, M.,
Fuks, Z.,
and Kolesnick, R. N.
(1994)
J. Exp. Med.
180,
525-535 |
| 19. |
Zumbansen, M.,
and Stoffel, W.
(1997)
J. Biol. Chem.
272,
10904-10909 |
| 20. |
Watts, J. D.,
Gu, M.,
Polverino, A. J.,
Patterson, S. D.,
and Aebersold, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7292-7296 |
| 21. | Watts, J. D., Gu, M., Patterson, S. D., Aebersold, R., and Polverino, A. J. (1999) Cell Death Differ. 6, 105-114[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Hofmann, K., and Dixit, V. M. (1998) Trends Biochem. Sci. 23, 374-377[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Tomiuk, S.,
Hofmann, K.,
Nix, M.,
Zumbansen, M.,
and Stoffel, W.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3638-3643 |
| 24. |
Liu, B.,
Hassler, D. F.,
Smith, G. K.,
Weaver, K.,
and Hannun, Y. A.
(1998)
J. Biol. Chem.
273,
34472-34479 |
| 25. | Fleischer, S., and Kervina, M. (1974) Methods Enzymol. 31, 6-41[Medline] [Order article via Infotrieve] |
| 26. | Swanson, M. A. (1955) Methods Enzymol. 2, 541-543[CrossRef] |
| 27. |
Widnell, C. C.,
and Unkeless, J. C.
(1968)
Proc. Natl. Acad. Sci. U. S. A.
61,
1050-1057 |
| 28. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve] |
| 29. | Hostetler, K. Y., and Yazaki, P. J. (1979) J. Lipid Res. 20, 456-463[Abstract] |
| 30. | Oefner, C., and Suck, D. (1986) J. Mol. Biol. 192, 605-632[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Liu, B.,
and Hannun, Y. A.
(1997)
J. Biol. Chem.
272,
16281-16287 |
| 32. |
Liu, B.,
Andrieu-Abadie, N.,
Levade, T.,
Zhang, P.,
Obeid, L. M.,
and Hannun, Y. A.
(1998)
J. Biol. Chem.
273,
11313-11320 |
| 33. | Tomiuk, S., Hofmann, K., Nix, M., Zumbansen, M., and Stoffel, W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8414a |
| 34. |
Oorni, K.,
Hakala, J. K.,
Annila, A.,
Ala-Korpela, M.,
and Kovanen, P. T.
(1998)
J. Biol. Chem.
273,
29127-29134 |
| 35. |
Veiga, M. P.,
Arrondo, J. L.,
Goni, F. M.,
and Alonso, A.
(1999)
Biophys. J.
76,
342-350 |
| 36. | Bennett, M. K., Garcia-Arraras, J. E., Elferink, L. A., Peterson, K., Fleming, A. M., Hazuka, C. D., and Scheller, R. H. (1993) Cell 74, 863-873[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Spence, M. W., and Burgess, J. K. (1978) J. Neurochem. 30, 917-919[CrossRef][Medline] [Order article via Infotrieve] |
| 38. |
Zhang, P.,
Liu, B.,
Jenkins, G. M.,
Hannun, Y. A.,
and Obeid, L. M.
(1997)
J. Biol. Chem.
272,
9609-9612 |
This article has been cited by other articles:
![]() |
J. E. Vance Thematic Review Series: Glycerolipids. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids J. Lipid Res., July 1, 2008; 49(7): 1377 - 1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Stoffel, B. Jenke, B. Holz, E. Binczek, R. H. Gunter, J. Knifka, J. Koebke, and A. Niehoff Neutral Sphingomyelinase (SMPD3) Deficiency Causes a Novel Form of Chondrodysplasia and Dwarfism That Is Rescued by Col2A1-Driven smpd3 Transgene Expression Am. J. Pathol., July 1, 2007; 171(1): 153 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Butler, R. E. Gordon, S. Gatt, and E. H. Schuchman Sperm Abnormalities in Heterozygous Acid Sphingomyelinase Knockout Mice Reveal a Novel Approach for the Prevention of Genetic Diseases Am. J. Pathol., June 1, 2007; 170(6): 2077 - 2088. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Modrak, D. V. Gold, and D. M. Goldenberg Sphingolipid targets in cancer therapy. Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Stoffel, B. Jenke, B. Block, M. Zumbansen, and J. Koebke Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development PNAS, March 22, 2005; 102(12): 4554 - 4559. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Modrak, T. M. Cardillo, G. A. Newsome, D. M. Goldenberg, and D. V. Gold Synergistic Inte |